Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Feb 1;99(3):447–456. doi: 10.1172/JCI119179

Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

D F Jelinek 1, K M Aagaard-Tillery 1, B K Arendt 1, T Arora 1, R C Tschumper 1, J J Westendorf 1
PMCID: PMC507818  PMID: 9022078

Abstract

Although IFN-alpha is commonly used as maintenance treatment for multiple myeloma patients, its effectiveness is varied. In this study, we have used a panel of IL-6 responsive myeloma cell lines that vary remarkably in responsiveness to IFN-alpha. Three cell lines were growth arrested by IFN-alpha; however, IFN-alpha significantly stimulated growth of the fourth cell line, KAS-6/1. Our studies have focused on elucidating the mechanism of differential IFN-alpha responsiveness. First, we have shown that IFN-alpha-stimulated growth of the KAS-6/1 cells did not result from induction of autocrine IL-6 expression. Second, analysis of Stats 1, 2, and 3 and IFN regulatory factor-1 (IRF-1) and IRF-2 activation failed to reveal differences between the IFN-alpha growth-arrested or growth-stimulated cells. Third, although IFN-alpha treatment of the IFN-alpha growth-inhibited cell lines reduced IL-6 receptor (IL-6R) expression, IFN-alpha also reduced KAS-6/1 IL-6R expression. Finally, although IFN-alpha treatment reduced IL-6R numbers on each cell line, analysis of Stat protein activation revealed that the receptors were still functional. We conclude that myeloma cell responsiveness to IFN-alpha is heterogeneous and that mechanisms of IFN-alpha-mediated growth inhibition other than IL-6R downregulation must exist in myeloma. Identification of these mechanisms may allow development of agents that are more universally effective than IFN-alpha.

Full Text

The Full Text of this article is available as a PDF (408.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthes J. C., Zhan Z., Gilchrest H., Egan R. W., Siegel M. I., Billah M. M. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Biochem J. 1995 Jul 1;309(Pt 1):175–180. doi: 10.1042/bj3090175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bladé J., López-Guillermo A., Tassies D., Montserrat E., Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol. 1991 Nov;79(3):523–525. doi: 10.1111/j.1365-2141.1991.tb08068.x. [DOI] [PubMed] [Google Scholar]
  3. Brenning G., Ahre A., Nilsson K. Correlation between in vitro and in vivo sensitivity to human leucocyte interferon in patients with multiple myeloma. Scand J Haematol. 1985 Nov;35(5):543–549. doi: 10.1111/j.1600-0609.1985.tb02826.x. [DOI] [PubMed] [Google Scholar]
  4. Brenning G., Jernberg H., Gidlund M., Sjöberg O., Nilsson K. The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline. Scand J Haematol. 1986 Oct;37(4):280–288. doi: 10.1111/j.1600-0609.1986.tb02313.x. [DOI] [PubMed] [Google Scholar]
  5. Brenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol. 1985 Aug;35(2):178–185. doi: 10.1111/j.1600-0609.1985.tb01568.x. [DOI] [PubMed] [Google Scholar]
  6. Browman G. P., Bergsagel D., Sicheri D., O'Reilly S., Wilson K. S., Rubin S., Belch A., Shustik C., Barr R., Walker I. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1995 Sep;13(9):2354–2360. doi: 10.1200/JCO.1995.13.9.2354. [DOI] [PubMed] [Google Scholar]
  7. Chin Y. E., Kitagawa M., Su W. C., You Z. H., Iwamoto Y., Fu X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996 May 3;272(5262):719–722. doi: 10.1126/science.272.5262.719. [DOI] [PubMed] [Google Scholar]
  8. Einhorn S., Fernberg J. O., Grandér D., Lewensohn R. Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1505–1510. doi: 10.1016/0277-5379(88)90342-2. [DOI] [PubMed] [Google Scholar]
  9. Friedman R. L., Manly S. P., McMahon M., Kerr I. M., Stark G. R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell. 1984 Oct;38(3):745–755. doi: 10.1016/0092-8674(84)90270-8. [DOI] [PubMed] [Google Scholar]
  10. Gao P. Q., Sims S. H., Chang D. C., Deisseroth A. B. Interferon-gamma priming effects in the activation and deactivation of ISGF3 in K562 cells. J Biol Chem. 1993 Jun 15;268(17):12380–12387. [PubMed] [Google Scholar]
  11. Gresser I. Antitumour effects of interferons: past, present and future. Br J Haematol. 1991 Oct;79 (Suppl 1):1–5. doi: 10.1111/j.1365-2141.1991.tb08108.x. [DOI] [PubMed] [Google Scholar]
  12. Gutterman J. U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198–1205. doi: 10.1073/pnas.91.4.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harada H., Kitagawa M., Tanaka N., Yamamoto H., Harada K., Ishihara M., Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science. 1993 Feb 12;259(5097):971–974. doi: 10.1126/science.8438157. [DOI] [PubMed] [Google Scholar]
  14. Harroch S., Gothelf Y., Watanabe N., Revel M., Chebath J. Interleukin-6 activates and regulates transcription factors of the interferon regulatory factor family in M1 cells. J Biol Chem. 1993 Apr 25;268(12):9092–9097. [PubMed] [Google Scholar]
  15. Harroch S., Revel M., Chebath J. Induction by interleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA. EMBO J. 1994 Apr 15;13(8):1942–1949. doi: 10.1002/j.1460-2075.1994.tb06463.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Harvey W. H., Harb O. S., Kosak S. T., Sheaffer J. C., Lowe L. R., Heerema N. A. Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade. Leuk Res. 1994 Aug;18(8):577–585. doi: 10.1016/0145-2126(94)90039-6. [DOI] [PubMed] [Google Scholar]
  17. Heslop H. E., Bianchi A. C., Cordingley F. T., Turner M., Chandima W., De Mel C. P., Hoffbrand A. V., Brenner M. K. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med. 1990 Dec 1;172(6):1729–1734. doi: 10.1084/jem.172.6.1729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ihle J. N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol. 1995;60:1–35. doi: 10.1016/s0065-2776(08)60582-9. [DOI] [PubMed] [Google Scholar]
  19. Imam A. M., Ackrill A. M., Dale T. C., Kerr I. M., Stark G. R. Transcription factors induced by interferons alpha and gamma. Nucleic Acids Res. 1990 Nov 25;18(22):6573–6580. doi: 10.1093/nar/18.22.6573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Jelinek D. F., Ahmann G. J., Greipp P. R., Jalal S. M., Westendorf J. J., Katzmann J. A., Kyle R. A., Lust J. A. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 1993 Nov 1;53(21):5320–5327. [PubMed] [Google Scholar]
  21. Jourdan M., Zhang X. G., Portier M., Boiron J. M., Bataille R., Klein B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol. 1991 Dec 15;147(12):4402–4407. [PubMed] [Google Scholar]
  22. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  23. Kishimoto T., Akira S., Narazaki M., Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995 Aug 15;86(4):1243–1254. [PubMed] [Google Scholar]
  24. Larner A. C., Chaudhuri A., Darnell J. E., Jr Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J Biol Chem. 1986 Jan 5;261(1):453–459. [PubMed] [Google Scholar]
  25. Ludwig H., Cohen A. M., Polliack A., Huber H., Nachbaur D., Senn H. J., Morant R., Eckhardt S., Günczler P., Seewann H. L. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol. 1995 May;6(5):467–476. doi: 10.1093/oxfordjournals.annonc.a059217. [DOI] [PubMed] [Google Scholar]
  26. McKean D. J., Podzorski R. P., Bell M. P., Nilson A. E., Huntoon C. J., Slack J., Dower S. K., Sims J. Murine T helper cell-2 lymphocytes express type I and type II IL-1 receptors, but only the type I receptor mediates costimulatory activity. J Immunol. 1993 Oct 1;151(7):3500–3510. [PubMed] [Google Scholar]
  27. Mellstedt H., Ahre A., Björkholm M., Holm G., Johansson B., Strander H. Interferon therapy in myelomatosis. Lancet. 1979 Feb 3;1(8110):245–247. doi: 10.1016/s0140-6736(79)90770-0. [DOI] [PubMed] [Google Scholar]
  28. Minami M., Inoue M., Wei S., Takeda K., Matsumoto M., Kishimoto T., Akira S. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3963–3966. doi: 10.1073/pnas.93.9.3963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Oken M. M. Standard treatment of multiple myeloma. Mayo Clin Proc. 1994 Aug;69(8):781–786. doi: 10.1016/s0025-6196(12)61100-8. [DOI] [PubMed] [Google Scholar]
  30. Palumbo A., Battaglio S., Napoli P., Omedè P., Fusaro A., Bruno B., Boccadoro M., Pileri A. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. Br J Haematol. 1994 Apr;86(4):726–732. doi: 10.1111/j.1365-2141.1994.tb04821.x. [DOI] [PubMed] [Google Scholar]
  31. Pestka S., Langer J. A., Zoon K. C., Samuel C. E. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777. doi: 10.1146/annurev.bi.56.070187.003455. [DOI] [PubMed] [Google Scholar]
  32. Portier M., Zhang X. G., Caron E., Lu Z. Y., Bataille R., Klein B. gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood. 1993 Jun 1;81(11):3076–3082. [PubMed] [Google Scholar]
  33. Sadowski H. B., Shuai K., Darnell J. E., Jr, Gilman M. Z. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science. 1993 Sep 24;261(5129):1739–1744. doi: 10.1126/science.8397445. [DOI] [PubMed] [Google Scholar]
  34. Sawamura M., Murayama K., Ui G., Matsushima T., Tamura J., Murakami H., Naruse T., Tsuchiya J. Plasma cell leukaemia with alpha-interferon therapy in myeloma. Br J Haematol. 1992 Nov;82(3):631–631. doi: 10.1111/j.1365-2141.1992.tb06484.x. [DOI] [PubMed] [Google Scholar]
  35. Schindler C., Darnell J. E., Jr Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621–651. doi: 10.1146/annurev.bi.64.070195.003201. [DOI] [PubMed] [Google Scholar]
  36. Schwabe M., Brini A. T., Bosco M. C., Rubboli F., Egawa M., Zhao J., Princler G. L., Kung H. F. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains. J Clin Invest. 1994 Dec;94(6):2317–2325. doi: 10.1172/JCI117596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sims J. E., Gayle M. A., Slack J. L., Alderson M. R., Bird T. A., Giri J. G., Colotta F., Re F., Mantovani A., Shanebeck K. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6155–6159. doi: 10.1073/pnas.90.13.6155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Tanaka N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M. S., Aizawa S., Mak T. W., Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell. 1994 Jun 17;77(6):829–839. doi: 10.1016/0092-8674(94)90132-5. [DOI] [PubMed] [Google Scholar]
  39. Tanaka N., Taniguchi T. Cytokine gene regulation: regulatory cis-elements and DNA binding factors involved in the interferon system. Adv Immunol. 1992;52:263–281. doi: 10.1016/s0065-2776(08)60877-9. [DOI] [PubMed] [Google Scholar]
  40. Taniguchi T., Harada H., Lamphier M. Regulation of the interferon system and cell growth by the IRF transcription factors. J Cancer Res Clin Oncol. 1995;121(9-10):516–520. doi: 10.1007/BF01197763. [DOI] [PubMed] [Google Scholar]
  41. Wagner B. J., Hayes T. E., Hoban C. J., Cochran B. H. The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. EMBO J. 1990 Dec;9(13):4477–4484. doi: 10.1002/j.1460-2075.1990.tb07898.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Westendorf J. J., Ahmann G. J., Armitage R. J., Spriggs M. K., Lust J. A., Greipp P. R., Katzmann J. A., Jelinek D. F. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 1994 Jan 1;152(1):117–128. [PubMed] [Google Scholar]
  43. Westendorf J. J., Ahmann G. J., Greipp P. R., Witzig T. E., Lust J. A., Jelinek D. F. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia. 1996 May;10(5):866–876. [PubMed] [Google Scholar]
  44. Williams B. R. Transcriptional regulation of interferon-stimulated genes. Eur J Biochem. 1991 Aug 15;200(1):1–11. doi: 10.1111/j.1432-1033.1991.tb21041.x. [DOI] [PubMed] [Google Scholar]
  45. Yamada G., Ogawa M., Akagi K., Miyamoto H., Nakano N., Itoh S., Miyazaki J., Nishikawa S., Yamamura K., Taniguchi T. Specific depletion of the B-cell population induced by aberrant expression of human interferon regulatory factor 1 gene in transgenic mice. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):532–536. doi: 10.1073/pnas.88.2.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yamanaka Y., Nakajima K., Fukada T., Hibi M., Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J. 1996 Apr 1;15(7):1557–1565. [PMC free article] [PubMed] [Google Scholar]
  47. Yang C. H., Shi W., Basu L., Murti A., Constantinescu S. N., Blatt L., Croze E., Mullersman J. E., Pfeffer L. M. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem. 1996 Apr 5;271(14):8057–8061. doi: 10.1074/jbc.271.14.8057. [DOI] [PubMed] [Google Scholar]
  48. Zhang X., Blenis J., Li H. C., Schindler C., Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science. 1995 Mar 31;267(5206):1990–1994. doi: 10.1126/science.7701321. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES